Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Status:
Completed
Trial end date:
2018-09-11
Target enrollment:
Participant gender:
Summary
This study will evaluate long-term safety and tolerability of pasireotide LAR in combination
with everolimus in advanced metastatic NET patients, who who have not progressed during 12
months of combination therapy with pasireotide LAR and everolimus